Tag: Astellas Pharma
Japan’s MHLW grants priority review for PADCEV and KEYTRUDA combo in urothelial cancer
In a significant development in the fight against urothelial cancer, Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has awarded ... Read More
Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More
Astellas Pharma to acquire avacincaptad pegol developer Iveric Bio for $6bn
Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around $5.9 billion with an aim to create ... Read More
Aurobindo Pharma announces FDA final approval for Amphotericin B Liposome for Injection
Aurobindo Pharma said that its fully-owned subsidiary — Eugia Pharma Specialities has secured final approval for Amphotericin B Liposome for Injection, 50 mg from the ... Read More
Astellas Pharma to acquire stake in biotech company Taysha GeneTherapies
Astellas Pharma has signed an agreement to acquire a 15% stake in US-based biotech company Taysha GeneTherapies through an investment of $50 million. As part ... Read More
Astellas hit by fatal event in ASPIRO clinical trial of AT132 in XLMTM
Astellas Pharma said that a participant in the ASPIRO clinical trial of AT132, who had developed a serious adverse event earlier this month, has passed away. The ... Read More
Astellas, FibroGen get extended Roxadustat approval in Japan for anemia of CKD
Roxadustat approval - Astellas Pharma and FibroGen have secured approval for EVRENZO (roxadustat) in Japan for the treatment of anemia associated with chronic kidney disease ... Read More
PADCEV, KEYTRUDA combination for advanced bladder cancer gets FDA breakthrough therapy status
PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been ... Read More
Astellas Pharma acquires US biotech company Xyphos Biosciences
Astellas acquisition of Xyphos : Japanese pharma company Astellas Pharma has acquired US biotech company Xyphos Biosciences in a deal worth up to $665 million ... Read More
Astellas, Seattle Genetics bag Padcev FDA approval for advanced urothelial cancer
Padcev FDA approval : Astellas Pharma and Seattle Genetics have bagged accelerated approval from the US Food and Drug Administration (FDA) for Padcev (enfortumab vedotin-ejfv) ... Read More